Therapyx, Inc.

LOUISVILLE, KY 40204

SBIR Award Summary

Total Number of Awards 18
Total Value of Awards $10.5MM
First Award Date 09/30/02
Most Recent Award Date 06/20/17

Key Personnel

Last Name Name Awards Contact
Lou Qiang Lou 2
Conway Thomas F Conway 10
Liu Yingru Liu 5
AUCI DOMINICK L AUCI 3

18 Awards Won

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 06/20/17 - 05/31/18

Abstract TGF?NanoCap® is an oral combination of nanoparticulate transforming growth factor beta 1 (TGF?) and all- trans retinoic acid (ATRA) in pre-clinical development for treatment of inflammatory bowel disease (IBD). Phase I studies provided proof-of-principle for efficacy in a murine model. Phase II work optimized therapeutic protocol, confi...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 02/14/17 - 01/31/18

ABSTRACT Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and it can be acquired repeatedly. Despite public health measures, the disease persists at an unacceptably high frequency; there is no vaccine against it, and resistance even to the latest generations of antibiotics con...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-15-269
Budget: 09/05/16 - 09/04/17

Abstract The disorders collectively known as inflammatory bowel disease (IBD) including Crohn?s disease (CD) and ulcerative colitis (UC) affect up to one and a half million Americans. Both result from uncontrolled chronic inflammatory activity in the GI tract. Most therapeutic agents act by down-regulating inflammation, are not curative and suff...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 06/01/15 - 05/31/16

DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite public health measures, the disease persists at an unacceptably high frequency; there is no vaccine against it, and resistance even to the latest gener...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 01/01/15 - 12/31/15

DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite public health measures, the disease persists at an unacceptably high frequency, and resistance even to the latest generations of antibiotics continues ...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-13-234
Budget: 06/15/14 - 05/31/15

DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite public health measures, the disease persists at an unacceptably high frequency;there is no vaccine against it, and resistance even to the latest genera...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 04/01/13 - 03/31/14

DESCRIPTION (provided by applicant): Phase I studies established proof-of-principle for the efficacy of oral sustained-release TGF?1 (TPX-6001) and ATRA (TPX-7001) nanoparticles in the treatment of IBD in a murine adoptive T-cell transfer model. Specifically, a two-week regimen of oral TPX-6001 and TPX-7001 achieved a 50-90 % reduction in the se...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-123
Budget: 02/01/13 - 01/31/14

DESCRIPTION (provided by applicant): Genital tract infection with Neisseria gonorrhoeae (gonorrhea) does not induce a state of specific protective immunity and can be acquired repeatedly. Despite public health measures, the disease persists at an unacceptably high frequency;there is no vaccine against it, and resistance even to the latest genera...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 04/01/12 - 03/31/13

DESCRIPTION (provided by applicant): Phase I studies established proof-of-principle for the efficacy of oral sustained-release TGF?1 (TPX-6001) and ATRA (TPX-7001) nanoparticles in the treatment of IBD in a murine adoptive T-cell transfer model. Specifically, a two-week regimen of oral TPX-6001 and TPX-7001 achieved a 50-90 % reduction in the se...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-10-050
Budget: 04/01/11 - 03/31/12

DESCRIPTION (provided by applicant): Phase I studies established proof-of-principle for the efficacy of oral sustained-release TGF?1 (TPX-6001) and ATRA (TPX-7001) nanoparticles in the treatment of IBD in a murine adoptive T-cell transfer model. Specifically, a two-week regimen of oral TPX-6001 and TPX-7001 achieved a 50-90 % reduction in the se...

Load More